Flow cytometric detection of Pig-A mutant red blood cells using an erythroid-specific antibody: Application of the method for evaluating the in vivo genotoxicity of methylphenidate in adolescent rats

Environmental and Molecular Mutagenesis

Volumn 51, Issue 2, 2010, Pages 138-145

  Dobrovolsky, Vasily N ^a   Boctor, Sherin Y ^a,b   Twaddle, Nathan C ^a   Doerge, Daniel R ^a   Bishop, Michelle E ^a   Manjanatha, Mugimane G ^a   Kimoto, Takafumi ^c   Miura, Daishiro ^c   Heflich, Robert H ^a   Ferguson, Sherry A ^a,b  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c TEIJIN PHARMA LIMITED   (Japan)

Author keywords

Glycosyl phosphotidylinositol anchor; HIS49; Micronucleus; N ethyl N nitrosourea; Ritalinic acid; Sprague Dawley rats

Indexed keywords

ANEUGEN; CD59 ANTIGEN; CLASTOGEN; ERYTHROCYTE ANTIBODY; ETHYLNITROSOUREA; METHYLPHENIDATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HIS49; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; GENE; GENE MUTATION; GENOTOXICITY; IN VIVO STUDY; INDUCED MUTATION; MALE; MICRONUCLEUS TEST; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PERINATAL PERIOD; PIG A GENE; RAT; SENSITIVITY AND SPECIFICITY; TOXICITY TESTING;

ALKYLATING AGENTS; ANIMALS; ANTIBODIES, MONOCLONAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DNA DAMAGE; ERYTHROCYTES; ETHYLNITROSOUREA; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE PROTEINS; METHYLPHENIDATE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY;

ANIMALIA; RATTUS; SUIDAE;

EID: 77249096480     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20519     Document Type: Article

References (22)

1. Andreazza AC, Frey BN, Valvassori SS, Zanotto C, Gomes KM, Comim CM, Cassini C, Stertz L, Ribeiro LC, Quevedo J, Kapczinski F, Berk M, Gonçalves CA. 2007. DNA damage in rats after treatment with methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 31:1282-1288.
2. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. 1999. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA 96:5209-5214.
3. Bakhtiar R, Tse FL. 2003. Toxicokinetic assessment of methylphenidate [Ritalin(R)] in a 13-week oral (gavage) toxicity study in rats using an enantiomeric liquid chromatography/tandem mass spectrometry assay. Rapid Commun Mass Spectrom 17:2160-2162.
4. Brodsky RA, Hu R. 2006. PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis. Leuk Lymphoma 47:1215-1221.
5. Bryce SM, Bemis JC, Dertinger SD. 2008. In vivo mutation assay based on the endogenous Pig-a locus. Environ Mol Mutagen 49:256-264.
6. EEC. 1986. Council directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations, and administrative provisions of the member states regarding the protection of animals used for experimental and other scientific purposes. Off J Eur Commun L358:1-29.
7. El-Zein RA, Abdel-Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL, Legator MS. 2005. Cytogenetic effects in children treated with methylphenidate. Cancer Lett 230:284-291.
8. Ferguson SA, Boctor SY. 2009. Use of food wafers for multiple daily oral treatments in young rats. J Am Assoc Lab Anim Sci 48:292-295.
9. Greenhill LL, Perel JM, Rudolph G, Feldman B, Curran S, Puig-Antich J, Gardner R. 2001. Correlations between motor persistence and plasma levels in methylphenidate-treated boys with ADHD. Int J Neuropsychopharmacol 4:207-215.
10. Laviola G, Macri S, Morley-Fletcher S, Adriani W. 2003. Risk-taking behavior in adolescent mice: Psychobiological determinants and early epigenetic influence. Neurosci Biobehav Rev 27:19-31.
11. Manjanatha MG, Shelton SD, Dobrovolsky VN, Shaddock JG, McGarrity LG, Doerge DR, Twaddle NW, Lin CJ, Chen JJ, Mattison DR, Morris SM. 2008. Pharmacokinetics, dose-range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice. Environ Mol Mutagen 49:585-593.
12. Miura D, Dobrovolsky VN, Kasahara Y, Katsuura Y, Heflich RH. 2008. Development of an in vivo gene mutation assay using the endogenous Pig-A gene: I. Flow cytometric detection of CD59-negative peripheral red blood cells and CD48-negative spleen T-cells from the rat. Environ Mol Mutagen 49:614-621.
13. Miura D, Dobrovolsky VN, Kimoto T, Kasahara Y, He.ich RH. 2009 Accumulation and persistence of Pig-A mutant peripheral red blood cells following treatment of rats with single and split doses of N-Ethyl-N- nitrosourea. Mutat Res 677:86-92.
14. Morris SM, Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Bishop ME, Manjanatha MG, Shelton SD, Doerge DR, Twaddle NC, Chen JJ, Lin CJ, Paule MG, Slikker W, Jr., Hotchkiss CE, Petibone D, Tucker JD, Mattison DR. 2009. The genetic toxicology of methylphenidate hydrochloride in non-human primates. Mutat Res 673:59-66.
15. Nishimura J, Murakami Y, Kinoshita T. 1999. Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease. Am J Hematol 62:175-182.
16. NTP. 1995. Toxicology and carcinogenesis studies of methylphenidate hydrochloride in F344/N rats and B6C3F1 mice. Research Triangle Park, NC: National Toxicology Program.
17. Quinn D, Wigal S, Swanson J, Hirsch S, Ottolini Y, Dariani M, Roffman M, Zeldis J, Cooper T. 2004. Comparative pharmacodynamics and plasma concentrations of D-threo-methylphenidate hydrochloride after single doses of D-threo-methylphenidate hydrochloride, and D,L-threo- methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43:1422-1429.
18. Quinn D, Bode T, Reiz JL, Donnelly GA, Darke AC. 2007. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. J Clin Pharmacol 47:760-766.
19. Teicher MH, Polcari A, Foley M, Valente E, McGreenery CE, Chang WW, McKay G, Midha KK. 2006. Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. J Child Adolesc Psychopharmacol 16:416-431.
20. Walitza S, Werner B, Romanos M, Warnke A, Gerlach M, Stopper H. 2007. Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder? Environ Health Perspect 115:936-940.
21. Wheeler TL, Eppolito AK, Smith LN, Huff TB, Smith RF. 2007. A novel method for oral stimulant administration in the neonate rat and similar species. J Neurosci Methods 159:282-285.
22. Witt KL, Shelby MD, Itchon-Ramos N, Faircloth M, Kissling GE, Chrisman AK, Ravi H, Murli H, Mattison DR, Kollins SH. 2008. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. J Am Acad Child Adolesc Psychiatry 47:1375-1383.